Dorsey & Whitney Trust CO LLC Lowers Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Dorsey & Whitney Trust CO LLC reduced its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 4.7% during the fourth quarter, HoldingsChannel reports. The fund owned 15,549 shares of the company’s stock after selling 773 shares during the period. Dorsey & Whitney Trust CO LLC’s holdings in Takeda Pharmaceutical were worth $206,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Smithfield Trust Co boosted its stake in Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Sage Rhino Capital LLC raised its holdings in Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company’s stock worth $157,000 after buying an additional 1,538 shares during the last quarter. Kovitz Investment Group Partners LLC lifted its stake in shares of Takeda Pharmaceutical by 7.0% in the third quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company’s stock worth $362,000 after buying an additional 1,670 shares in the last quarter. Aaron Wealth Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 7.2% during the fourth quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company’s stock valued at $331,000 after buying an additional 1,670 shares during the last quarter. Finally, Versant Capital Management Inc purchased a new stake in Takeda Pharmaceutical during the 4th quarter valued at $26,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 1.0 %

Shares of NYSE:TAK opened at $14.90 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.22. The company has a market cap of $47.39 billion, a P/E ratio of 37.24, a PEG ratio of 0.24 and a beta of 0.46. The stock’s fifty day moving average price is $13.66 and its 200-day moving average price is $13.90.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Sell-side analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.